1-9 of 9
Marion Dahlke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial

Regis Peffault De Latour, Austin G. Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos de Castro, Samopriyo Maitra, Philippe Ferber, Marion Dahlke, Antonio M Risitano
Journal: Blood
Blood (2024) 144 (Supplement 1): 4087.
https://doi.org/10.1182/blood-2024-200763
Published: 2024
Journal Articles

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

Antonio M Risitano, Bing Han, Austin G. Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw Maciejewski, Josefin Snellman, Olivier Somenzi, Randall Winnette, Samopriyo Maitra, Shujie Li, Marion Dahlke, Regis Peffault De Latour
Journal: Blood
Blood (2024) 144 (Supplement 1): 4079.
https://doi.org/10.1182/blood-2024-203532
Published: 2024
Journal Articles

Patient Experience Interviews with a Novel Treatment Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Carlos De Castro, Phillip Scheinberg, Bing Han, Susan Vallow, Georgina Bermann, Marion Dahlke, Zhixin Wang, Rakesh Kumar, Gavin Dickie, Caitlyn Lowe, Kaelyn Rupinski, Amber Nieves, Regis Peffault De Latour
Journal: Blood
Blood (2023) 142 (Supplement 1): 7339.
https://doi.org/10.1182/blood-2023-186840
Published: 2023
Journal Articles

Clinical Breakthrough Hemolysis (BTH) during Monotherapy with the Oral Factor B Inhibitor Iptacopan Is Generally Not Severe and Managed without Treatment Discontinuation: 48-Week Data from the Phase III Apply-PNH and Appoint-PNH Trials in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Regis Peffault De Latour, Austin Kulasekararaj, Phillip Scheinberg, Philippe Ferber, Tomasz Lawniczek, Christine Thorburn, Marion Dahlke, Antonio M Risitano
Journal: Blood
Blood (2023) 142 (Supplement 1): 1338.
https://doi.org/10.1182/blood-2023-179377
Published: 2023
Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Antonio M Risitano, Austin Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yasutaka Ueda, Carlos de Castro, Eros Di Bona, Morag Griffin, Saskia MC Langemeijer, Hubert Schrezenmeier, Wilma Barcellini, Vitor AQ Mauad, Jens Panse, Philippe Schafhausen, Suzanne Tavitian, Eloise Beggiato, Anna Gaya, Wei-Han Huang, Toshio Kitawaki, Abdullah Kutlar, Jaroslaw P. Maciejewski, Rosario Notaro, Vinod Pullarkat, Jörg Schubert, Louis Terriou, Michihiro Uchiyama, Flore Sicre De Fontbrune, Camilla Frieri, Ferras Alashkar, Shreyans Gandhi, Rakesh Kumar, Christine Thorburn, Samopriyo Maitra, Susan Solar-Yohay, Tomasz Lawniczek, Marion Dahlke, Régis Peffault De Latour
Journal: Blood
Blood (2023) 142 (Supplement 1): 571.
https://doi.org/10.1182/blood-2023-180780
Published: 2023
Journal Articles

Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M Risitano, Regis Peffault De Latour, Jun Ho Jang, Eng-Soo Yap, Christian Bartels, Guido Junge, Marion Dahlke, Irina Baltcheva
Journal: Blood
Blood (2023) 142 (Supplement 1): 5643.
https://doi.org/10.1182/blood-2023-179960
Published: 2023
Journal Articles

Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial

Antonio M Risitano, Bing Han, Austin Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw P. Maciejewski, Josefin Snellman, Ranjan Tiwari, Marion Dahlke, Régis Peffault de Latour
Journal: Blood
Blood (2023) 142 (Supplement 1): 4084.
https://doi.org/10.1182/blood-2023-180866
Published: 2023
Journal Articles

Patient-Reported Improvements in Fatigue and Health-Related Quality of Life in the Phase 3 Studies Apply-PNH and Appoint-PNH Evaluating the Use of Iptacopan in C5 Inhibitor-Treated and Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Antonio M Risitano, Carlos M de Castro, Bing Han, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Phillip Scheinberg, Yasutaka Ueda, Susan Vallow, Georgina Bermann, Marion Dahlke, Rakesh Kumar, Regis Peffault de Latour
Journal: Blood
Blood (2023) 142 (Supplement 1): 487.
https://doi.org/10.1182/blood-2023-179035
Published: 2023
Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Regis Peffault de Latour, Alexander Roeth, Austin Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M de Castro, Eros Di Bona, Hubert Schrezenmeier, Saskia MC Langemeijer, Wilma Barcellini, Suzanne Tavitian, Jens Panse, Philippe Schafhausen, Vitor AQ Mauad, Cecile Kerloeguen, Rafael Levitch, Rakesh Kumar, Christine Thorburn, Samopriyo Maitra, Marion Dahlke, Antonio M Risitano
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-2.
https://doi.org/10.1182/blood-2022-171469
Published: 2022